ASLAN Pharmaceuticals - ADR Peer Comparison

$0.60

$-- (--%)

As on 16-Aug-2024 09:30EDT

Market cap

$2 Mln

Revenue (TTM)

$12 Mln

P/E Ratio

--

P/B Ratio

2.1

Div. Yield

0 %

Edit

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Market cap ($ Mln)	2	8,191
Revenue ($ Mln)	12	16
Net Profit ($ Mln)	-35.03	-460.47
Net Margin (%)	-291.89	-2,792.07
RoE (%)	--	-109.97
Price to Earnings	--	--
Price-To-Book	2.14	14.51

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Operating Revenue	12.00	16.49
Cost of Revenue	0.00	5.85
Gross Profit	11.65	-5.63
Operating Expenses	46.85	488.87
Operating Profit (EBIT)	-34.85	-490.37
Other Income	0.00	0.00
Profit before Tax	-34.90	-459.91
Provision for Tax	0.13	0.56
Profit after Tax (Net Income)	-35.03	-460.47
Minority Interest	0.00	0.00
Consolidated Profit	-1.89	-99.54

Liabilities ($ Mln)

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Shareholder's Funds	-17.96	564.46
Minority Interest	0.00	0.00
Non-Current Liabilities	19.35	478.78
Current Liabilities	19.60	84.10
Total Liabilities	24.63	1,243.30

Assets ($ Mln)

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Non-Current Assets	0.41	267.77
Current Assets	20.58	859.58
Total Assets	24.63	1,243.30
Total Debt*	26.67	368.30
Net Current Assets	0.97	775.47

Cashflow ($ Mln)

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Cash From Operating Activities	-46.36	-342.30
Cash Flow from Investing Activities	-0.01	--
Cash from Financing Activities	10.72	548.62
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
ROCE (%)	-148.58	-42.38
ROE (%)	1,796.92	-109.97
ROA (%)	-56.43	-41.77
EBIT Margin (%)	-184.02	-2,791.72
Net Margin (%)	-291.89	-2,792.07
Cash Profit Margin (%)	--	0.00

Growth Ratios

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Revenue Growth (%)	0.00	--
EBIT Growth (%)	59.18	-15.48
Net Profit Growth (%)	38.99	-18.12
EPS Growth (%)	69.97	-8.93
Book Value Growth (%)	-244.26	12.79

Valuation Ratios

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Price / Earnings	-5.19	-15.87
Price / Book Value	-17.28	10.19
Dividend Yield (%)	--	--
EV/EBITDA	-5.42	-13.10
Market Cap ($ Cr)	--	--

Solvency Ratios

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Debt to Equity	-1.08	0.60
Short term debt to equity ratio	-0.41	0.01
Current Ratio	1.05	10.22
Quick Ratio	1.05	10.12
Interest Coverage	-7.91	-42.46

Operating Efficiency Ratios

	ASLAN Pharmaceuticals - ADR	Cerevel Therapeutics Holdings (CERE)
Debtors to sales (%)	1.43	30.09
Asset Turnover	0.19	0.01
Receivable days	5.22	--
Inventory Days	--	-132.81
Payable days	10,849.14	711.55
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly